TWD 86.9
(-12.4%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 84.35 Million TWD | -3.57% |
2022 | 87.47 Million TWD | 78.13% |
2021 | 49.1 Million TWD | -5.45% |
2020 | 51.93 Million TWD | -11.75% |
2019 | 58.85 Million TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 72.26 Million TWD | -14.33% |
2024 Q2 | 72.26 Million TWD | 0.0% |
2023 Q4 | 84.35 Million TWD | 0.0% |
2023 FY | 84.35 Million TWD | -3.57% |
2023 Q3 | 84.35 Million TWD | -5.06% |
2023 Q1 | 88.85 Million TWD | 1.58% |
2023 Q2 | 88.85 Million TWD | 0.0% |
2022 Q3 | 87.47 Million TWD | 0.0% |
2022 FY | 87.47 Million TWD | 78.13% |
2022 Q4 | 87.47 Million TWD | 0.0% |
2021 FY | 49.1 Million TWD | -5.45% |
2020 FY | 51.93 Million TWD | -11.75% |
2019 FY | - TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
BIONET Corp. | 626.46 Million TWD | 86.535% |
DIVA Laboratories, Ltd. | 210.93 Million TWD | 60.01% |
Genetics Generation Advancement Corp. | 164.9 Million TWD | 48.849% |
Welgene Biotech Co.,Ltd. | 247.89 Million TWD | 65.973% |
TFBS Bioscience Inc. | 187.43 Million TWD | 54.997% |